Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effects of Primary Physician Presence in AI-Synthesized SGLT2 Inhibitor Educational Videos for Heart Failure (AI-PRESENCE HF)

9 de noviembre de 2026 actualizado por: In-Cheol Kim, Keimyung University Dongsan Medical Center

Effects of Primary Physician Presence in SGLT2 Inhibitor-Focused Heart Failure Educational Videos During Outpatient Waiting Time on Patient Satisfaction and Educational Effectiveness : A Randomized 2x2 Factorial Study

The purpose of this study is to evaluate the effect of the primary attending physician's presence in educational videos on patient satisfaction and educational effectiveness.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

The videos, generated using AI technology, focus on SGLT2 inhibitors and are provided to heart failure patients during their outpatient clinic waiting time.

In this single-center, randomized, 2x2 factorial study, participants will be assigned to one of four groups based on two factors: the specific doctor featured in the video (Doctor A vs. Doctor B) and the physician's role presentation (presented as the patient's actual attending physician vs. a non-attending general cardiologist).

All participants will watch the assigned educational video during their waiting time and then proceed with their scheduled outpatient consultation. After the consultation, participants will complete a single survey. The survey will assess overall patient satisfaction, the perceived usefulness of the education, and the objective understanding of the video's key messages regarding heart failure management and SGLT2 inhibitors.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

150

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Incheol Kim, MD
  • Número de teléfono: +82-53-258-4625
  • Correo electrónico: kimic@dsmc.or.kr

Ubicaciones de estudio

      • Daegu, Corea del Sur, 42601
        • Reclutamiento
        • Keimyung University Dongsan Medical Center
        • Contacto:
          • Hyemin Kwon
          • Número de teléfono: +82-53-258-6691
          • Correo electrónico: irbdsmc@naver.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

19 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults aged 19 years or older.
  • Patients diagnosed with heart failure or those visiting the cardiology outpatient clinic with suspected heart failure symptoms (e.g., dyspnea, edema).
  • Patients currently taking or scheduled to be prescribed SGLT2 inhibitors for the treatment of heart failure.
  • Patients who are able to watch the educational video during the outpatient waiting time and complete the survey after the consultation.
  • Patients who fully understand the purpose and procedures of this study and voluntarily provide written informed consent.

Exclusion Criteria:

  • Patients who do not understand the contents of this study or do not consent to the study due to cognitive decline, etc.
  • Patients with expected acute exacerbation of heart failure or a life expectancy of 1 year or less.
  • Patients who have difficulty watching the video due to visual or hearing impairments.
  • Patients scheduled for heart failure-related surgery or procedures.
  • Patients who are currently participating in, or have participated in within the past 6 months, another intervention study related to heart failure education.
  • Other patients deemed inappropriate for study participation by the investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación factorial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Doctor A - Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as their primary physician.

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Otros nombres:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Comparador activo: Doctor A - Non-Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as a general cardiologist (non-attending).

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Otros nombres:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Experimental: Doctor B - Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as their primary physician.

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Otros nombres:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Comparador activo: Doctor B - Non-Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as a general cardiologist (non-attending).

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Otros nombres:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Patient Satisfaction Score
Periodo de tiempo: Immediately after the outpatient clinic visit (Day 0)

Patient satisfaction regarding the positive impact and helpfulness of the educational video on the subsequent outpatient consultation process. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates a higher level of patient satisfaction.

Immediately after the outpatient clinic visit (Day 0)
Educational Usefulness Score
Periodo de tiempo: Immediately after the outpatient clinic visit (Day 0)

The perceived usefulness of the educational video in understanding heart failure treatment methods, specifically the role, effects, and precautions of SGLT2 inhibitors. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates greater perceived educational usefulness and understanding.

Immediately after the outpatient clinic visit (Day 0)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Educational Content Delivery Effectiveness Score
Periodo de tiempo: Immediately after the outpatient clinic visit (Day 0)

An objective assessment of the patient's understanding of the video's key messages, such as heart failure management and SGLT2 inhibitor information. It is evaluated based on the number of correct answers to 4 multiple-choice questions derived directly from the video's core content. The total score ranges from 0 to 4, where 1 point is awarded for each correct answer. A higher score indicates a better understanding and a higher level of correct knowledge acquisition.

Immediately after the outpatient clinic visit (Day 0)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

21 de agosto de 2026

Finalización primaria (Estimado)

31 de julio de 2027

Finalización del estudio (Estimado)

31 de julio de 2027

Fechas de registro del estudio

Enviado por primera vez

9 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2026-06-008

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .